GlassScriptPhysician profile
Rony R Lee
NPI 1518944834
$1,105.33
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $227 · 2021: $374 · 2022: $97.00 · 2023: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $164.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $499.75 | 2019-2023 | Relistor |
| Galt Pharmaceuticals, LLC | $116.05 | 2023 | Orphengesic Forte |
| Indivior INC. | $85.55 | 2019-2021 | |
| Horizon Therapeutics Plc | $56.77 | 2019-2020 | |
| Orexo US, INC. | $48.13 | 2019-2021 | |
| Zyla Life Sciences, INC. | $42.10 | 2020 | |
| Daiichi Sankyo INC. | $35.77 | 2019 | |
| Pfizer INC. | $35.75 | 2020 | |
| Redhill Biopharma INC. | $31.46 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $28.71 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $24.14 | 2019 | |
| Alkermes, INC. | $22.57 | 2021 | |
| Ibsa Pharma INC. | $15.81 | 2023 | Tirosint, Licart |
| Arbor Pharmaceuticals, INC. | $13.96 | 2019 | |
| Abbvie INC. | $13.10 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $12.27 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.17 | 2022 | |
| Eisai INC. | $11.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rony Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.